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Introduction  and  aim:  Biomarkers  have  emerged  as  interesting  predictors  of  risk  in  patients
with acute  coronary  syndromes  (ACS).  The  aim  of  this  study  was  to  determine  the  utility  of
the combined  measurement  of  cystatin  C  (CysC),  C-reactive  protein  (CRP),  N-terminal  pro-
brain natriuretic  peptide  (NT-proBNP)  and  red  blood  cell  distribution  width  (RDW)  in  the  risk
stratification  of  patients  with  ACS.
Methods:  In  this  prospective  study  including  682  patients  consecutively  admitted  to  a  coronary
care unit  for  ACS,  baseline  measurements  of  CysC,  CRP,  NT-proBNP  and  RDW  were  performed.
Patients were  categorized  on  the  basis  of  the  number  of  elevated  biomarkers  at  presentation.
The primary  outcome  was  6-month  mortality.
Results:  The  number  of  biomarkers  elevated  on  admission  (study  score)  was  an  independent
predictor  of  6-month  mortality;  patients  with  four  biomarkers  elevated  on  admission  had  a
significantly  higher  risk  of  6-month  mortality  compared  with  patients  with  none  or  one.  In
addition, in  patients  with  high  risk  defined  by  the  GRACE  score,  our  multimarker  score  was  able
to further  categorize  their  risk  of  6-month  mortality.
Conclusions:  A  multimarker  approach  using  CysC,  NT-proBNP,  CRP  and  RDW  was  an  independent
predictor  of  6-month  mortality  and  added  prognostic  information  to  the  GRACE  risk  score  in
loaded from http://www.elsevier.pt, day 01/12/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.patients with  ACS  and  high  risk  defined  by  GRACE,  with  increasing  mortality  in  patients  with  a
higher number  of  elevated  biomarkers  on  admission.
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Abordagem  multimarcadores  com  a  cistatina  C,  pro-peptídeo  natriurético  tipo  B
cerebral,  proteína  C  reativa  e  índice  de  anisocitose  na  estratificação  de  risco
dos  doentes  com  síndrome  coronária  aguda
Resumo
Introdução  e  objetivo:  Os  biomarcadores  têm  surgido  como  interessantes  preditores  de  risco
em doentes  com  síndrome  coronária  aguda  (SCA).  O  objetivo  deste  estudo  foi  definir  a  utilidade
da combinação  da  cistatina  C  (CysC),  da  proteína  C  reativa  (CRP),  a  porção  N-terminal  do
peptídeo natriurético  tipo  B  (NT-proBNP)  e  do  índice  de  anisocitose  (RDW)  na  estratificação  de
risco dos  doentes  com  SCA.
Métodos:  Estudo  prospetivo,  incluindo  682  doentes  admitidos  consecutivamente  na  nossa
unidade coronária  por  SCA.  À  admissão  foi  feito  o  doseamento  plasmático  da  CysC,  CRP,  NT-
-proBNP e  RDW.  Os  doentes  foram  categorizados  de  acordo  com  o  número  de  biomarcadores
elevados à  admissão.  O  evento  primário  estudado  foi  a  mortalidade  aos  seis  meses.
Resultados:  O  número  de  biomarcadores  elevados  à  admissão  (score  estudado)  foi  preditor
independente  de  mortalidade  aos  seis  meses;  os  doentes  com  quatro  biomarcadores  elevados  à
admissão  tiveram  um  risco  de  morte  aos  seis  meses  significativamente  superior  aos  doentes  sem
nenhum ou  com  apenas  um  biomarcador  elevado.  Adicionalmente,  nos  doentes  com  alto  risco
definido pelo  score  GRACE,  o  nosso  score  multimarcadores  teve  a  capacidade  de  os  categorizar
adicionalmente  quanto  ao  risco  de  morte  aos  seis  meses.
Conclusão:  A  abordagem  multimarcadores  baseada  na  CysC,  NT-proBNP,  CRP  e  RDW  foi  preditor
independente  de  mortalidade  aos  seis  meses  e  proporcionou  informação  prognóstica  adicional
nos doentes  de  alto  risco  definido  pelo  score  GRACE,  com  maior  da  mortalidade  nos  doentes
com maior  número  de  biomarcadores  elevados  à  admissão.
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ACS  acute  coronary  syndrome
AUC  area  under  the  receiver  operating  character-
istic  curve
BNP  brain  natriuretic  peptide
CG  Cockcroft-Gault  equation
CI  confidence  interval
CRP  C-reactive  protein
cTnI  cardiac  troponin  I
CysC  cystatin  C
GFR  glomerular  filtration  rate
hsCRP  high  sensitivity  C-reactive  protein
MI  myocardial  infarction
NT-proBNP  N-terminal  pro-brain  natriuretic  peptide
LV  left  ventricular
NSTE-ACS  non-ST-segment  elevation  acute  coronary
syndrome
OR  odds  ratio
PCI  percutaneous  coronary  intervention
RDW  red  blood  cell  distribution  width
STE-ACS  ST-segment  elevation  acute  coronary  syn-
dromentroduction
arious  risk  factors  have  been  identified  in  patients  with





coring  systems  that  enable  the  clinician  to  stratify  risk  and
uide  treatment.1 In  recent  years,  a  deeper  understanding
f  the  pathobiology  of  atherothrombosis  as  the  underlying
echanism  of  ACS  has  directed  studies  towards  the  evalua-
ion  of  novel  serum  biomarkers  as  potential  diagnostic  tools
or  the  clinical  setting.2,3 Recognition  of  the  importance  of
ncluding  all  the  major  mechanisms  of  ACS  in  risk  stratifica-
ion  has  increased  the  appeal  of  the  multimarker  approach.
owever,  the  ideal  biomarkers  and  the  ideal  combination  to
mprove  risk  stratification  have  not  been  defined.
The  aim  of  this  study  was  to  assess  the  value  of  a  multi-
arker  approach  with  cystatin  C  (CysC),  C-reactive  protein
CRP),  N-terminal  pro-brain  natriuretic  peptide  (NT-proBNP)
nd  red  blood  cell  distribution  width  (RDW)  in  the  risk  strat-
fication  of  patients  with  ACS.
Another  objective  of  the  study  was  to  determine  the  hier-
rchy  of  these  biomarkers  in  terms  of  predictive  power  for
-month  mortality.
ethods
tudy  design  and  population
f  a  total  of  902  consecutive  patients  admitted  to  our
epartment’s  coronary  care  unit  between  July  1,  2009
nd  June  30,  2011  with  a  diagnosis  of  ACS,  we  prospec-
ively  studied  682  patients.  The  time  between  the  onset
f  ACS  symptoms  and  the  time  of  blood  sampling  to  assess
iomarkers  was  <24  hours.  The  remaining  220  patients  were
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symptom  onset  and  the  time  of  blood  sampling;  or  if  at  least
one  of  the  four  laboratory  predictors  had  not  been  assessed
on  admission  (clotted  blood  sample  or  failure  to  request  the
laboratory  study).  The  excluded  patients  were  slightly  older
than  the  study  population,  but  did  not  differ  significantly  in
other  baseline  characteristics  (Table  1).
The  study  was  approved  by  the  ethics  committee  and  all
patients  provided  written  informed  consent.
The  patients  included  in  the  study  presented  a  history
of  chest  pain  at  rest  or  symptoms  suggestive  of  ACS,  the
most  recent  episode  being  up  to  24  hours  before  admission.
Symptoms  could  be  associated  with  persistent  or  transient
ST-segment  elevation,  ST-segment  depression,  or  T-wave
inversion  on  the  ECG,  or  elevated  biomarkers  of  cardiac
injury.  The  biomarkers  used  were  cardiac  troponin  I  (cTnI)
and  the  MB  fraction  of  creatinine  kinase  (CK-MB)  and  the
99th  percentile  of  a  reference  population  was  employed
as  the  diagnostic  threshold.  Patients  with  unstable  angina
and  normal  admission  ECG  were  also  included  (n=24).  Left
ventricular  (LV)  ejection  fraction  was  assessed  by  transtho-
racic  echocardiography  1--2  days  after  admission.  In  patients
with  ST-segment  elevation  ACS  (STE-ACS)  echocardiography
was  performed  after  cardiac  catheterization  as  long  as  a
mechanical  complication  was  not  suspected.  In  patients  with
non-ST-segment  elevation  ACS  (NSTE-ACS)  echocardiography
was  performed  before  cardiac  catheterization  and  usually
within  24  hours  of  admission.
The  four  laboratory  predictors  were  considered  to  be
elevated  when  CysC  >0.95  mg/l  (normal  0.53--0.95);  CRP
>5.0  mg/l  (<5);  NT-proBNP  >125  pg/ml  (<125)  and  RDW  >14%
(11.6--14.0),  which  were  the  upper  limit  values  of  a  normal
population.  Glomerular  filtration  rate  (GFR)  was  estimated
by  the  Cockcroft-Gault  (CG)  formula  and  renal  dysfunction
was  defined  as  GFR  <60  ml/min/1.73  m2.4
Follow-up  and  adverse  events
The  study’s  primary  outcome  was  cumulative  all-cause  mor-
tality  at  six  months.  Follow-up  and  confirmation  of  adverse
events  were  by  telephone  contact  and  by  consultation  of
the  hospital’s  databases  and  records.  Six-month  follow-up
was  achieved  in  633  patients  (92.8%  of  the  study  popula-
tion).  The  majority  of  patients  lost  for  follow-up  had  moved
away  or  were  from  other  areas  of  reference  and  so  contact
was  not  possible;  their  baseline  characteristics  did  not  differ
significantly  from  those  of  the  study  population  (Table  2).
Statistical  analysis
Patients  were  divided  into  five  groups  according  to  the
number  of  elevated  laboratory  predictors  on  admission:  G0
(n=24),  in  whom  none  of  the  four  biomarkers  was  elevated  at
admission;  G1  (n=158),  in  whom  one  biomarker  was  elevated
at  admission;  G2  (n=281),  in  whom  two  biomarkers  were  ele-
vated  at  admission;  G3  (n=156),  in  whom  three  biomarkers
were  elevated  at  admission;  and  G4  (n=63),  in  whom  all
biomarkers  were  elevated  at  admission.  The  groups  were
compared  in  terms  of  baseline  characteristics.  Categorical
variables  were  expressed  as  percentages  and  conti-
nuous  variables  as  means  ±  standard  deviation  or  medi-






sing  the  Student’s  t  test  or  the  Mann-Whitney  U  test  for
ontinuous  variables  and  the  chi-square  test  or  Fisher’s
xact  test  for  categorical  variables,  as  appropriate.  Mul-
ivariate  linear  regression  analysis  was  performed  to
etermine  which  of  the  following  variables  were  asso-
iated  with  a  higher  number  of  laboratory  predictors
levated  on  admission:  age  and  gender;  history  of  dia-
etes,  hypertension,  smoking,  myocardial  infarction  (MI),
enal  failure,  stroke/transient  ischemic  attack,  atrial  fibril-
ation,  or  coronary  artery  bypass  grafting  (CABG);  previous
edication  with  aspirin,  thienopyridines,  beta-blockers,
ngiotensin-converting  enzyme  inhibitors  or  angiotensin
eceptor  blockers  and  statins;  Killip  class,  heart  rate,  GFR,
emoglobin  and  type  of  ACS  on  admission.
To  assess  the  association  between  a  higher  number  of
iomarkers  elevated  on  admission  and  6-month  mortality,
ultivariate  logistic  regression  analysis  was  performed,  the
odels  being  constructed  with  the  number  of  predictors  ele-
ated  on  admission  as  a  categorical  variable  and  including
our  other  covariables  associated  with  6-month  mortality,
iven  the  small  number  of  events  in  the  study.  The  thresh-
ld  for  retaining  a  variable  in  the  final  model  was  set
t  p<0.1.  The  variables  included  were  age,  Killip  class  on
dmission,  LV  systolic  dysfunction,  coronary  revasculariza-
ion  and  the  number  of  elevated  biomarkers  on  admission.
o  assess  whether  the  study  score  (number  of  laboratory
redictors  elevated  on  admission)  was  a  predictor  of  mortal-
ty  independent  of  the  GRACE  score,5 the  GRACE  score  was
ncluded  in  a second  multivariate  logistic  regression  model
hich  included  the  multimarker  score,  LV  systolic  dysfunc-
ion,  coronary  revascularization  and  GRACE  score.  Age  and
illip  class  were  not  included  in  this  second  model  because
hey  are  already  included  in  the  GRACE  score.
Kaplan-Meier  survival  curves  were  constructed  to  com-
are  event-free  survival  at  six  months  according  to  the
umber  of  elevated  laboratory  predictors  on  admission,
sing  the  log-rank  test.  A  value  of  p<0.05  was  considered
tatistically  significant.  All  statistical  tests  were  two-sided.
he  statistical  software  used  was  Statistical  Package  for  the
ocial  Sciences  (SPSS)  version  17.0  (SPSS  Inc.,  Chicago,  Ill).
The  hierarchy  of  the  biomarkers  in  terms  of  predictive
ower  for  6-month  mortality  was  assessed  by  comparing
he  areas  under  the  receiver-operating  characteristic  curve
AUCs).  This  calculation  and  comparison  was  performed  with
edCalc  version  12.2.1.0  (MedCalc  Software,  Mariakerke,
elgium).
Given  the  known  value  of  the  GRACE  score  in  the  risk
tratification  of  patients  with  ACS,  we  conducted  a  stratified
nalysis  of  6-month  mortality  according  to  the  number  of
levated  biomarkers  in  patients  with  low,  intermediate  and
igh  risk  according  to  their  GRACE  score  (in  both  NSTE-ACS
nd  STE-ACS).
esults
aseline  characteristicsf  the  682  patients  enrolled  in  the  study,  356  (52.2%)  had
T-segment  elevation  MI,  302  (44.3%)  had  non-ST-segment
levation  MI,  and  24  (3.5%)  had  a  final  diagnosis  of  unsta-
le  angina.  On  admission,  24  (3.5%)  patients  were  in  group
130  C.  Vieira  et  al.
Table  1  Differences  in  baseline  characteristics  between  included  and  excluded  patients.
Included  (n=682)  Excluded  (n=220)  p
Demographic
Age  (years)  64±13  66±13  0.027
Male (%)  77.9  76.8  0.747
CV risk  factors  (%)
Diabetes  26.4  27.3  0.797
Hypertension  63.5  68.2  0.206
Dyslipidemia 53.5  53.6  0.976
Active smoker  30.2  25.9  0.223
CV history  (%)
MI  15.2 17.7  0.382
Stroke 7.5  8.2  0.733
PAD 2.9  3.2  0.850
PCI 6.6  7.3  0.729
CABG 4.1  3.6  0.757
Chronic kidney  disease  3.4  4.1  0.632
Previous medication  (%)
Aspirin  24.5 26.4  0.576
Thienopyridines  7.2 6.4 0.678
Beta-blockers  22.1 19.1  0.337
ACEIs/ARBs 45.0 43.6 0.721
Statins  34.2 36.8 0.006
Clinical  presentation
ST-segment  elevation  (%)  52.2  55.0  0.400
Killip class  >I  (%)  21.8  26.4  0.382
SBP (mmHg)  129±26  126±29  0.204
DBP (mmHg)  78±15  76±16  0.128
HR (bpm)  76±19  78±21  0.128
Hemoglobin (g/dl)  13.9±2.2  13.6±1.9  0.109
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0,  158  (23.2%)  in  G1,  281  (41.2%)  in  G2,  156  (22.9%)  in
3  and  63  (9.2%)  in  G4.  The  demographic  characteristics
f  the  study  population  according  to  the  number  of  ele-
ated  biomarkers  on  admission  are  shown  in  Table  3.  Patients
ith  a  higher  number  of  elevated  biomarkers  on  admis-
ion  were  older  (p  for  trend  <0.001),  more  likely  to  be
emale  (p<0.001),  and  had  a  higher  prevalence  of  diabetes
p=0.001)  and  hypertension  (p<0.001).  These  patients  more
ften  had  a  history  of  MI  (p<0.001),  CABG  (p=0.021)  and
troke  (p<0.001),  and  on  admission  more  often  presented
ith  NSTE-ACS  (p<0.001),  Killip  class  >I  (p<0.001)  and  lower
ean  hemoglobin  (p<0.001).
Table  4  shows  patients’  in-hospital  treatment  and  angio-
raphic  and  echocardiographic  characteristics  according  to
he  number  of  laboratory  predictors  elevated  on  admission.
hree-vessel  and  left  main  disease  (p<0.001)  and  LV  dysfunc-
ion  (p<0.001)  were  more  frequent  in  patients  with  a  higher
umber  of  laboratory  predictors  elevated  on  admission,  who
ere  also  less  often  revascularized  (p<0.001).  Furthermore,
ercutaneous  coronary  intervention  (PCI)  (p<0.0001)  and
hienopyridines  (p<0.0001)  and  beta-blockers  were  used  less
ften  in  these  patients,  whereas  diuretics  (p=0.003),  aldos-
erone  antagonists  (p<0.0001)  and  intravenous  inotropics





ial infarction; PAD: peripheral arterial disease; PCI: percutaneous
utcomes
ixteen  (2.4%)  patients  died  during  initial  hospitalization
nd  23  (3.4%)  died  within  six  months  of  hospital  discharge.
he  primary  outcome  (all-cause  mortality)  was  recorded
n  39  (5.7%)  patients  during  6-month  follow-up.  Patients
ith  a  higher  number  of  laboratory  predictors  elevated  on
dmission  had  increased  in-hospital  (p<0.0001)  and  6-month
ortality  (p<0.0001).  Table  4  lists  the  in-hospital  events  and
igure  1  shows  Kaplan-Meier  curves  for  the  primary  outcome
uring  follow-up  according  to  the  number  of  laboratory  pre-
ictors  elevated  on  admission.
In  Table  5,  the  results  of  multivariate  logistic  regression
nalysis  are  presented  for  6-month  mortality  accord-
ng  to  the  number  of  laboratory  predictors  elevated
n  admission.  After  adjustment  for  the  previously  men-
ioned  possible  confounding  factors,  patients  with  four
aboratory  predictors  elevated  on  admission  had  a  higher
ncidence  of  6-month  mortality  compared  to  patients  with
one  or  one,  with  an  odds  ratio  (OR)  of  10.66  (95%  confi-
ence  interval  [CI],  2.11--53.93;  p=0.004).  When  the  GRACE
isk  score  was  included  in  the  second  model  (Table  6),  the
umber  of  biomarkers  elevated  on  admission  was  still  an
ndependent  predictor  of  6-month  mortality;  patients  with
Multimarker  risk  stratification  in  acute  coronary  syndrome  131







Age  (years)  64±13  63±14  0.794
Male (%)  78.0  75.5  0.681
CV risk  factors  (%)
Diabetes  26.4  26.5  0.982
Hypertension  64.0  57.1  0.338
Dyslipidemia  54.2  44.9  0.209
Active smoker 29.7 36.7  0.301
CV history  (%)
MI  15.3  14.3  0.846
Stroke 7.7  4.1  0.348
PAD 2.8  4.1  0.621
PCI 7.0  2.0  0.182
CABG 4.1  4.1  0.993
Chronic kidney  disease  3.3  4.5  0.661
Previous medication  (%)
Aspirin  25.6 10.2 0.016
Thienopyridines  7.4 4.1 0.383
Beta-blockers  22.3 20.4 0.762
ACEIs/ARBs  44.9  46.9  0.779
Statins 35.1  22.4  0.073
Clinical presentation
ST-segment  elevation  (%)  52.0  55.1  0.673
Killip class  >I  (%)  21.8  26.4  0.303
SBP (mmHg)  129±26  130±27  0.666
DBP (mmHg)  78±15  81±15  0.172
HR (bpm)  76±19  73±15  0.315
Hemoglobin (g/dl)  14.0±2.2  13.4±2.0  0.092
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CABG: coronary artery bypass grafting; CV: car-
diovascular; DBP: diastolic blood pressure; HR: heart rate; MI: myocardial infarction; PAD: peripheral arterial disease; PCI: percutaneous





















Figure  1  Kaplan-Meier  curves  for  6-month  mortality  accord-
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4  times  greater  risk  of  6-month  mortality  than  patients  with
one  or  one.
The  AUCs  for  6-month  mortality  of  CysC,  NT-proBNP,  CRP
nd  RDW  (Figure  2)  of  all  the  patients  included  in  the  study
ere,  respectively,  0.84  (p<0.0001),  0.83  (p<0.0001),  0.75
p<0.0001)  and  0.64  (p=0.0036).  There  was  no  statistically
ignificant  difference  between  the  predictive  power  of  CysC
nd  NT-proBNP  (differences  in  AUC);  however,  CysC  and  NT-
roBNP  had  stronger  predictive  power  than  CRP  and  RDW,
nd  CRP  had  stronger  predictive  power  than  RDW  (Figure  2).
Among  patients  with  a  high  GRACE  risk  score,  our  score
as  able  to  further  stratify  risk,  in  both  patients  with
TE-ACS  (Figure  3)  and  patients  with  NSTE-ACS  (Figure  4).
atients  with  low  and  intermediate  risk  had  a  very  low
ortality  in  our  population.  In  patients  with  NSTE-ACS  and
ntermediate  GRACE  risk,  those  with  four  elevated  biomark-
rs  on  admission  had  high  mortality;  in  patients  admitted
or  STE-ACS,  all  patients  with  four  biomarkers  elevated  on
dmission  were  in  the  high  risk  group  defined  by  the  GRACE
core  (Figure  3), while  in  patients  admitted  for  NSTE-ACS
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Age  (years)  53±11  58±12  62±13  68±13  76±9  <0.0001
Female (%)  8.3  15.2  18.1  32.7  36.5  <0.0001
CV risk  factors  (%)
Diabetes  33.3  14.6  27.0  32.1  36.5  0.001
Hypertension  58.3  55.7  60.1  67.9  88.9  <0.0001
Dyslipidemia  66.7  52.5  54.4  53.2  47.6  0.607
Active smoker 50.0  37.3  35.2  17.9  12.7  <0.0001
CV history  (%)
MI  4.2  14.6  10.3  21.2  28.6  <0.0001
Stroke 0.0  4.4  3.9  10.3  27.0  <0.0001
PAD 4.2  1.3  3.6  4.5  4.8  0.579
PCI 12.5  8.2  4.6  7.1  6.6  0.400
CABG 0.0  1.9  2.8  7.7  7.9  0.021
Previous medication  (%)
Aspirin  16.7 23.4  19.2  28.8  42.9  0.001
Thienopyridines  0.0 3.2 6.8  12.8  7.9  0.010
Beta-blockers  12.5 18.4  17.8  28.8  38.1  0.001
ACEIs/ARBs  33.3 35.4 39.1  55.1  74.6  <0.0001
Statins 50.0 28.5 29.9 39.7  47.6  0.006
Clinical presentation
ST-segment  elevation  (%)  45.8  58.2  58.4  45.5  28.6  <0.0001
Killip class  >I  (%)  0.0  6.3  18.9  34.0  52.4  <0.0001
SBP (mmHg)  131±19  127±24  128±25  129±28  137±29  0.098
DBP (mmHg)  82±12  78±13  79±15  76±17  79±16  0.222
HR (bpm)  72±17  74±18  76±18  77±19  83±23  0.030
Renal failure  (%)a 4.2  6.3  11.7  35.9  74.2  <0.0001
Hemoglobin  (g/dl)  15.0±1.4  14.2±1.5  14.2±1.7  13.6±3.2  12.1±2.3  <0.0001
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CABG: coronary artery bypass grafting; CV: car-
diovascular; DBP: diastolic blood pressure; HR: heart rate; MI: myocardial infarction; PAD: peripheral arterial disease; PCI: percutaneous
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nd  with  low  risk  according  to  the  GRACE  score,  there  were
o  patients  with  four  elevated  biomarkers.
iscussion
he  present  study  demonstrates  that  a  multimarker
pproach  with  CysC,  NT-proBNP,  CRP  and  RDW  has  value
n  the  risk  stratification  of  patients  admitted  with  ACS.
e  found  that  a  higher  number  of  elevated  biomarkers,
easured  on  admission  by  the  same  laboratory,  was  progres-
ively  associated  with  an  increased  incidence  of  in-hospital
nd  6-month  mortality  in  an  unselected  population  of
atients  admitted  for  ACS.  Moreover,  in  multivariate  logistic
egression  analysis,  the  study  score  (number  of  biomark-
rs  elevated  on  admission)  was  a  predictor  of  mortality
ndependently  of  other  important  variables,  including  the
RACE  score;  patients  with  four  biomarkers  elevated  on
dmission  had  a  significantly  higher  risk  of  6-month  mortal-
ty  than  those  with  none  or  one.  When  the  population  was




nd  high  risk,  our  score  was  able  to  further  stratify  risk
n  both  STE-ACS  and  NSTE-ACS.  Patients  with  low  risk  had
 very  low  mortality  in  our  population.  In  patients  with
STE-ACS  and  intermediate  GRACE  risk,  those  with  four  ele-
ated  biomarkers  on  admission  had  high  mortality.  This  may
e  taken  into  account  in  the  risk  stratification  of  these
atients  and  help  in  clinical  decision-making  and  manage-
ent.  Another  important  fact  is  that  patients  with  four
iomarkers  elevated  on  admission  were  only  at  intermedi-
te  or  high  risk  defined  by  GRACE,  with  none  in  the  low
isk  category.  Therefore,  having  four  biomarkers  elevated
n  admission  indicates  significantly  higher  risk  and  may  be
sed  in  addition  to  conventional  risk  scores  to  complement
isk  stratification.
As  in  other  registries,  patients  at  higher  risk  (as  reflected
y  higher  biomarker  scores)  were  treated  less  often  with
n  invasive  treatment  strategy,  which  goes  against  current
uidelines.  This  ‘treatment  paradox’  may  have  contributed
o  greater  risk  in  patients  with  a  higher  score.
CysC  and  NT-proBNP  were  the  strongest  predictors,  sim-
lar  in  terms  of  discriminatory  power,  followed  by  CRP  and
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Table  4  Treatment,  angiographic  and  echocardiographic  characteristics,  and  in-hospital  events  according  to  the  number  of












In-hospital  medication  (%)
(%) 100  100  100  100  100
Thienopyridines  100  99.4  98.6  100  88.9  <0.0001
Beta-blockers  87.0  93.7  89.3  87.2  71.4  <0.0001
ACEIs/ARBs 91.3  87.3  89.0  90.3  84.1  0.710
Statins 100  100  99.3  100  99.6  0.420
Nitrates 17.4 22.2 34.3  33.3  20.0  0.003
UFH 41.7 40.5 40.6 27.6  27.0  0.024
LMWH 62.5 60.1 63.3 75.0 76.2 0.017
GP  IIb/IIIa  inhibitors  0.0  14.6  11.7  11.5  6.3  0.190
Revascularization  95.3  87.2  82.4  67.3  55.8  <0.0001
Diuretics 0.0  15.6  22.6  54.7  76.7  <0.0001
Aldosterone antagonists  0.0  6.3  15.7  28.0  33.3  <0.0001
IV inotropics  0.0  1.3  3.6  11.0  14.3  <0.0001
Procedures (%)
Cardiac  catheterization 100  100  99.3 96.2 87.3  <0.0001
PCI 81.0 71.8 65.5 59.3  41.0  <0.0001
CABG 14.3 15.4 16.9 8.0 14.8  0.167
Left main  disease  0.0  6.3  8.9  7.3  23.2  <0.0001
Three-vessel  disease  29.2  18.4  17.1  25.8  42.9  <0.0001
LVSD 9.1  44.9  58.5  59.4  63.3  <0.0001
In-hospital events  (%)
Killip  class  II-IV  0.0  12.0  28.8  48.1  71.4  <0.0001
Mortality 0.0  0.6  1.1  3.2  11.1  <0.0001
Reinfarction 0.0  2.5  3.6  1.9  3.2  0.771
Ischemic stroke  0.0  1.3  1.1  0.6  0.0  0.868
Hemorrhagic  stroke  0.0  0.9  0.7  0.6  1.6  0.692
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CABG: coronary artery bypass grafting; CV: car-
diovascular; GP: glycoprotein; IV: intravenous; LMWH: low molecular weight heparin; LVSD: left ventricular systolic dysfunction (ejection
interv
p
best  of  our  knowledge,  this  is  the  first  study  adopting  a
multimarker  approach  with  these  specific  markers.  James
et  al.  made  an  important  contribution  to  the  grow-
ing  evidence  demonstrating  that  combining  a  biomarker
Table  5  Independent  predictors  of  6-month  mortality  on
multivariate  logistic  regression  analysis.
Variable  OR  (95%  CI)  p
Age  1.06  (1.02--1.10)  0.005
LV dysfunction  0.80  (0.35--1.82)  0.593
Killip  class  on
admission  >1
2.54  (1.12--5.78)  0.026
Revascularization  0.80  (0.36--1.78)  0.582
Laboratory  predictors
G2/G0G1  1.38  (0.27--7.13)  0.703
G3/G0G1  2.90  (0.58--14.43)  0.193
Document downloaded from http://www.elsevier.pt, day 01/12/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.fraction <50% on echocardiography); PCI: percutaneous coronary 
finally  RDW.  This  result  may  be  also  taken  into  account  in
clinical  practice  when  stratifying  risk.
In  the  present  study,  we  included  a  marker  of  hemody-
namic  stress  (NT-proBNP),  one  of  inflammation  (CRP),  one  of
renal  dysfunction  (CysC),  and  RDW,  which  covers  more  than
one  mechanism  (nutritional  deficiencies,  renal  failure  and
inflammatory  stress).6,7 Various  studies  have  shown  that  NT-
proBNP,  CRP,  CysC,  and  RDW  are  also  associated  with  adverse
outcomes  in  patients  with  ACS  independently  of  hemody-
namic  stress,  inflammation  and  renal  dysfunction.6--18 In
addition,  all  of  these  biomarkers  are  commonly  used  in
clinical  assessment  of  patients  with  ACS  and  are  readily
available,  which  is  also  an  important  factor  when  choos-
ing  a  biomarker.  This  specific  combination  was  chosen  not
only  on  the  basis  of  the  evidence  in  the  above-mentioned
studies,  but  also  because  they  were  used  individually  in
the  risk  stratification  of  our  population  of  ACS  patients
in  other  studies,  in  which  they  were  good  predictors  of
outcome.7A  large  number  of  candidate  biomarkers  have  been
investigated  in  numerous  studies,  with  the  aim  of  further
improving  diagnosis  and  risk  assessment  in  patients  with
ACS.6--31ention; UFH: unfractionated heparin.
Some  studies  have  shown  that  a  multimarker  approach
rovides  prognostic  information  in  patients  with  ACS.  To  theG4/G0G1  10.66  (2.11--53.93)  0.004
CI: confidence interval; G0G1: groups 0 and 1; G3: group 3; G4:
group 4 (see text); LV: left ventricular.
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40 60 80 100
Labo ratory   predictor AU C  95%  CI  p 
CysC   0.838   0.807 -0.866 <0.0001
NT-proBN P  0.825   0.79 3-0.854   <0.0001
CRP 0.75 3 0.71 7-0.78 6 <0.000 1
RDW  0.64 4 0.60 5-0.68 1 0.003 6
Comparison  betwee n 
labo ratory  predictors
Diff erence  be tween  
AUCs
95%  CI  p
CysC_NT-proBN P  0.012 6 -0 .0704-0.095 7 0.766 1
CysC_CR P  0.084 8 0.0014-0.16 8 0.004 6
CysC_RDW  0.19 4 0.104-0.28 5 <0.000 1
NT-proBNP_CR P 0.072 2 0.0195-0.16 4 0.032 8
NT-proBNP_RD W  0.18 2 0.0698-0.29 4 0.001 5
CPR_RDW  0.11 0 0.00510-0.22 4 0.041 1
Figure  2  Receiver-operating  curves  and  AUCs  of  the  four
biomarkers  for  6-month  mortality.  AUC:  area  under  the  receiver-
operating  characteristic  curve  for  6-month  mortality;  CRP:
C-reactive  protein;  CysC:  cystatin  C;  NT-proBNP:  N-terminal


































Figure  3  Six-month  mortality  in  ST-elevation  acute  coronary
syndromes  according  to  GRACE  risk  score  and  the  number  of
biomarkers  elevated  on  admission.  *No  patients  with  four  ele-




































Figure  4  Six-month  mortality  in  non-ST-elevation  acute  coro-
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ated biomarkers  in  this  risk  category.
f  hemodynamic  stress  (brain  natriuretic  peptide  [BNP]
r  NT-proBNP)  or  of  inflammation  (high  sensitivity  C-
eactive  protein  [hsCRP])  with  a biomarker  of  necrosis
cTnI)  enhances  risk  assessment  in  patients  with  ACS.32
nother  study,  assessing  the  same  biomarkers  simultane-
usly  (cTnI,  CRP  and  BNP),  showed  that  a  multimarker
pproach  improves  the  risk  stratification  of  patients  with
STE-ACS.33 Tello-Montoliu  et  al.  found  that  a  multimarker
pproach  based  on  cTnT,  CRP,  and  NT-proBNP,  but  not  D-
imers,  provides  added  information  to  the  TIMI  risk  score  in
erms  of  ACS  prognosis  at  six  months.34 Möckel  et  al.  evalu-
ted  the  importance  of  various  biomarkers  (cTnI,  NT-proBNP,
sCRP,  placental  growth  factor,  lipoprotein-associated  phos-
holipase  A2  (Lp-PLA2),  D-dimers,  whole  blood  choline  and
lasma  choline)  in  patients  with  ACS  and  aimed  to  define
heir  hierarchy  with  respect  to  the  prediction  of  major
dverse  cardiac  events  over  a 42-day  follow-up  period.35
hey  used  logistic  regression  synergistically  with  classi-
cation  and  regression  tree  (CART)  analysis  to  define  a
ultimarker  strategy  and  the  cutoff  values  and  sequencing
eeded  to  optimize  risk  stratification  in  a  low-  to  moderate-
isk  emergency  department  population.  They  found  that  a
ombination  of  NT-proBNP,  whole  blood  choline  and  Lp-PLA2
ith  cutoffs  identified  by  CART  analysis  was  optimal  for  risk
tratification  and  superior  to  all  other  possible  combinations
f  markers.
Table  6  Independent  predictors  of  6-month  mortality  on
multivariate  logistic  regression  analysis.
Variable  OR  (95%  CI)  p
LV  dysfunction  0.676  (0.29--1.55)  0.356
Revascularization  1.55  (0.67--3.57)  0.304
Laboratory  predictors
G2/G0G1  1.22  (0.23--6.41)  0.811
G3/G0G1  2.96  (0.60--14.61)  0.182
G4/G0G1  13.86  (2.83--67.97)  0.001
GRACE  risk  score  1.03  (1.02--1.04)  <0.0001
CI: confidence interval; G0G1: groups 0 and 1; G3: group 3; G4:
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Limitations
Although  our  study  was  prospective  in  nature,  it  was  a
non-randomized  observational  study  conducted  in  a  single
center,  so  the  results  may  have  been  influenced  by  con-
founding  factors,  identified  or  not,  and  thus  no  causality  can
be  determined.  Besides,  few  events  occurred,  which  may
limit  extrapolation  of  the  results  to  the  general  population
of  patients  with  ACS.  In  addition,  our  analysis  is  based  on
only  one  measurement  of  all  biomarkers,  and  other  studies,
perhaps  using  sequential  samples,  are  warranted  to  explore
whether  the  prognostic  information  changes  over  time.
Conclusions
A  multimarker  approach  using  CysC,  NT-proBNP,  CRP  and
RDW  was  an  independent  predictor  of  6-month  mortality
and  added  prognostic  information  to  the  GRACE  risk  score
in  patients  with  ACS  and  high  risk  defined  by  GRACE,  with
increasing  mortality  in  patients  with  a  higher  number  of
elevated  biomarkers  on  admission.
Individually,  CysC  and  NT-proBNP  are  the  strongest  pre-
dictors.
Since  the  pathophysiology  of  ACS  is  complex,  a  combina-
tion  of  markers  representing  different  mechanisms  may  be
used  in  the  future  instead  of  a  single  marker.  Other  studies
are  needed  to  find  combinations  of  ideal  markers  in  addition
to  clinical  risk  factors.
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